Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus FOVANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus FOVANE.
CENTRAX vs FOVANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by inhibiting reuptake of serotonin at the synaptic cleft.
10-30 mg orally, 3-4 times daily.
Adults: 10 mg orally twice daily.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing, steady-state achieved by day 3.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: 60% unchanged; fecal: 30% (as metabolites); biliary: 10%.
Category C
Category C
Benzodiazepine
Benzodiazepine